Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Drug Profile

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Alternative Names: Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Tc99m tilmanocept; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 18 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; National Cancer Institute (USA); National Institute of Health Clinical Center; Navidea Biopharmaceuticals; Norgine; University of California, San Diego
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase II Cardiovascular disorders; Cervical cancer; Kaposi's sarcoma; Rheumatoid arthritis
  • Phase I Liver metastases; Non-alcoholic steatohepatitis
  • Clinical Phase Unknown Crohn's disease
  • No development reported Colorectal cancer; Endometrial cancer

Most Recent Events

  • 06 Nov 2019 Navidea Pharmaceuticals completes enrolment in its phase I trial for Kaposi Sarcoma in USA (NCT03157167)
  • 30 Oct 2019 Interim efficacy data from a phase IIb NAV3-31 trial in Rheumatoid arthritis (Diagnosis) released by Navidea Biopharmaceuticals
  • 04 Sep 2019 Navidea Biopharmaceuticals plans a phase IIb (NAV3-32) trial for Rheumatoid arthritis (Diagnosis) in the United Kingdom in December 2019 (NCT04078191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top